[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","no6do8eifq17ts5wed5nrzu9g","revision",2,"title","Adlai Nortye 与礼来和默克合作评估 AN4035 联合西妥昔单抗疗法","originalTitle","6-K - Adlai Nortye Group Ltd. (0001944552) (Filer)","summary","Adlai Nortye 与礼来和默克 KGaA 合作评估 AN4035 联合西妥昔单抗疗法。该合作旨在探索癌症治疗新方案。该 press release 作为 6-K 报告附件发布。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-15T11:00:04.000Z","discoveredAt","2026-10-15T11:03:44.505Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",43,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","ftUR029QpUHo",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","9a3034ab-8e87-4724-bba4-07a0c864d459","Adlai Nortye 与礼来、默克合作评估癌症疗法",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2026

Commission File Number: 001-41773

Adlai Nortye Group Ltd.

77 Robinson Road

#20-01, Robinson 77

Singapore 068896

(Address of principal executive offices)

Indicate by check mark whether the registrant files\nor will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form\n20-F ☐ Form 40-F

CONTENT

On October 15, 2026, Adlai Nortye Group Ltd.\n(previously known as Adlai Nortye Ltd.) (“Adlai Nortye” or the “Company”) issued a press release entitled “Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab”, a copy of the press release is attached\nto this Form 6-K as Exhibit 99.1.

Exhibits

\n \n \n \n \n \n \n \n \n

Exhibit No.		Description
99.1		Press Release: Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

SIGNATURES

Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Adlai Nortye Group Ltd.

	By:	/s/ Yang Lu
	Name:	Yang Lu
	Title:	Chief Executive Officer and \n Chairman of Board of Directors

Date: October 15, 2026

","zhKind","complete","ANL","公司与财报","并购","aihot","/items/no6do8eifq17ts5wed5nrzu9g","https://www.sec.gov/Archives/edgar/data/1944552/000121390026109576/0001213900-26-109576-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]